Clinical trials: HIV Seronegative
Anal Neoplasm
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
This is a phase 2, open-label efficacy study of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) in adult men and women who are human immunodeficiency virus (HIV) negative with histologically…
- Trial name
- NCT03499795
- Testing
- VGX-3100, CELLECTRA™ 5PSP
- Where
- 3 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Inovio Pharmaceuticals
HIV Infections
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
The purpose of this study is to evaluate the safety and pharmacokinetics of PC-1005 gel when used as a rectal microbicide in HIV-uninfected men and women (cis or transgender) with a history of consensual receptive anal…
- Trial name
- NCT03408899
- Testing
- PC-1005 gel
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Vaginosis, Candidiasis
Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
This research study is about vaginal infections such as bacterial vaginosis, yeast infections, and trichomoniasis. Usually, these infections can be treated with medication, but sometimes they come back after treatment.
- Conditions
- Bacterial Vaginosis, Candidiasis, Trichomoniasis
- Trial name
- NCT01230814
- Testing
- Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
- Where
- 4 sites in United States, Kenya
- Volunteers
- 234 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
AIDS, HIV Infections
Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers
GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or…
- Trial name
- NCT00434512
- Testing
- HIV vaccine 732461
- Where
- Belgium
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults.
- Trial name
- NCT03239483
- Testing
- Dapivirine gel
- Where
- 3 sites in United States, Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Hepatitis C
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
The investigator believes simeprevir concentrations are unchanged when administered in combination with dolutegravir relative to administration alone.
- Trial name
- NCT02404805
- Testing
- dolutegravir, simeprevir
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HIV Prevention
Rectal Microbicide Acceptability, Tolerability and Adherence
MTN-035 is a multi-site, randomized-sequence, three-period, open label crossover study that will enroll approximately 210 participants randomized (1:1:1:1:1:1) to one of six sequences of rectal microbicide placebo product…
- Trial name
- NCT03671239
- Where
- 7 sites in United States, Malawi and 3 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Microbicide Trials Network
HIV Infections, Health Volunteers
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and…
- Trial name
- NCT02990325
- Testing
- ABX464 150mg, ABX464 50mg
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Abivax S.A.